Latest Drugwonks' Blog is pleased to be part of a blogposium on Clinical Informatics, a neighborhood of folks with a passion to advance understanding on how bioinformatics and electronic patients records can improve health care. Jack Mason is the blogposium’s chair. He can be contacted at

Yesterday the CDC reported that life expectancy rose faster and death rates declined faster last year than in the past 30 because of new medicines. This bodes well for those getting the Medicare drug benefit in record numbers. But meanwhile Families USA wants to shove seniors into a VA style plan that limits access to these new medicines. Limiting access to new drugs and keeping them off formulary is a form of rationing and way to keeping formulary closed, ,which itself is a bargaining tool for driving down drug costs. In fact a study by Columbia University’s Frank Lichtenberg shows that the VA drug lag has actually increased death rates and reduced life expectancy among seniors. This is what is going on in the UK by the way where breakthrough by breakthrough the government is finding ways to say no to drugs for cancer, Alzheimer’s, MS and diabetes that increase life expectancy and quality of wellbeing. The justification of the VA and UK are similarly and depressingly striking. Actually studies show that limiting access drives up total costs and makes seniors sicker. Why would Families USA want that? Perhaps their hatred of drug companies outweighs their concern for the lives of seniors. Ron “The Godfather” Pollack the Don of Families USA wants everyone to believe that the VA just hands the off formulary medicines like candy after a friendly sort of negotation. Not so. Even the non-formulary drugs have to be discounted by at least 40 percent or you can’t get them. Getting on the formulary costs even more. So if you are biotech company that makes no money what incentive do you have to even try? No wonder the VA drug lag is growing and seniors are suffering as a result. Imagine if this little drill was applied to Medicare as a whole just like the Godfather wants?

Kiss me Kate

  • 04.19.2006

Yesterday the UK’s National Institute of Clinical Excellence (which goes by its Orwellian acronym of NICE) rejected Exubera (inhaled insulin) for NHS use on the grounds that the drug isn’t “cost-effective.” That means they don’t want to pay for it — not because it doesn’t work or it isn’t an advance — but because, well, they just don’t want to pay the additional 10 pounds (about $17.83) per week for those patients who would prefer inhaling rather than injecting their insulin. NICE’s dismissal of resultant savings from enhanced compliance and decreased complications? Total.

Dr. Kate Lloyd, the UK medical director for Pfizer (Exubera is a Pfizer product) called the decision “perverse and short-sighted.” It’s refreshing to hear such a clear and unambiguous shot across the bow from a pharmaceutical company.

Kiss me Kate.

Not surprisingly Diabetes UK (the largest diabetes patient organization in Britain) is — no pun intended — up in arms. Says Simon O’Neill, their director of care and policy, “The government has put patient choice on the NHS agenda. Diabetes UK is disappointed that the (NICE) guidance on inhaled insulin does not reflect this as we believe it could offer an alternative treatment in improving the lives of some people with diabetes.”

To which Dr. Andrea Sutcliffe (NICE’s deputy chief executive) responds, “The clinical experts we asked advised us that using injected insulin is not usually a concern for the majority of people with diabetes.”

Well … what about a sizable minority? Once again we witness the victory of equality vs. quality — the hallmark of government-sponsored “universal health care.” If you believe in cost-based medicine (referred to most commonly in the US by the equally Orwellian moniker of “evidence-based medicine”), then this is what you get. And you better get used to it … or get involved in the debate.

Prime Minister Blair admits that Britain’s health care is at a “crunch point,” but insists that the UK is still on an historic “end to traditional waiting” by 2008.

Makes sense to me. Disallow all new treatments and I too would predict an historic end to waiting — as well as a permanent end to quality health care.

Let’s not allow what’s going on “over there” go unrecognized over here.

Here’s an editorial from the Rocky Mountain News. That fresh mountain air certainly produces some clear-headed thinking.

Don’t target ads in drug-buying bill
Bill has one good idea, and one very bad one

Is Senate Bill 1 right for Colorado? If it did nothing more than let the state join a purchasing pool that cuts Medicaid drug spending, we would be inclined to say yes.

But to again paraphrase the TV ads, SB 1 has some serious side effects. The most dangerous is an onerous disclosure provision that would force drug companies to spend money defending their advertising budgets rather than, say, producing life-saving treatments.

If the disclosure requirement remains in SB 1, which is scheduled for a Senate vote today, we urge Gov. Bill Owens to veto the bill should it ever reach his desk.

That would be an unfortunate necessity if proponents of SB 1 are right: They say the state could save $20 million of $170 million it is spending on Medicaid drugs this year.

That may be an exaggeration. State health officials suggest the savings would be more like $3 million to $4 million. Still, that’s real money.

Under the bill, the state department of health policy would join a purchasing pool with other states to buy drugs for Medicaid recipients. People who earn too much to get Medicaid (up to $50,000 for a four-person household) but do not have medical insurance or whose policies do not pay for prescriptions could join the pool for $25 a year and purchase drugs at the discounted rate.

We supported a somewhat similar bill last year that Owens vetoed. We oppose SB 1, however, because of its inexplicable disclosure requirements, which could have been written by Ralph Nader. Asserting that advertising and lobbying leads to “an inordinate and unnecessary escalation of the cost of prescription drugs to consumers,” the bill would force every pharmaceutical company to detail its marketing budget to the state.

Every year, each drug maker would have to list promotions directed toward “any physician, medical student, hospital, nursing home, pharmacist, health benefit plan,” etc. We’re guessing that would include an accounting for the pens pharmaceutical reps hand out to receptionists.

They would also have to report all gifts worth more than $50, and naturally, how much they spend on lobbying, and who got the money.

Why? The Naderite left has long claimed that recent advances in medical science are mainly an illusion. Instead, drug companies largely repackage similar formulations and use promotional gimmicks to hoodwink doctors into prescribing new medications their patients don’t need.

Tell that to the arthritis patient who lives a relatively normal life because she can take Celebrex rather than megadoses of aspirin, or the diabetes sufferer who can test his own blood sugar with a pocket monitor.
It’s the business of shareholders and corporate boards to decide how much money a company spends on promotion and marketing. Lawmakers and bureaucrats should butt out.

Besides, if drug makers were forced to satisfy elaborate disclosure mandates, that would divert their focus from healing people — which is why, in its current form, SB 1 offers the wrong diagnosis.

I gave out the wrong address to the new medical news media watch website… It is I apologize for confusing people more than I usually do. Thanks to Antoine Clarke for picking up the boo-boo. The link to the Health news review rating of the CBS news treatment of the Evista study is posted below as is the review itself. As I noted in my last post, I think their review underscores the need for the oncology community to get on with the job of tailoring treatments according to how well people respond to certain cancer drugs. I have included an article that deals specifically with tamoxifen and other estrogen modifying agents and pharmacogenomics below.

This story reports on a potentially important development in the prevention of breast cancer among high risk, postmenopausal women.

The story is clear that this is an existing drug for osteoporosis that has not been approved by the FDA for use in breast cancer prevention. The story also does not make claims about when it may be approved for that purpose. There is no obvious disease mongering; the story accurately represents the prevalence and seriousness of breast cancer

Although there is mention of a clinical trial, the story does not describe the study design. Also not mentioned was the fact that the results have not yet been published or peer reviewed, so interpretation of the clinical significance of these results are difficult at this time. Benefits of treatment are quantified in relative terms only. The viewer is told that raloxifene and tamoxifen both reduce the incidence of breast cancer by about 50%, however there is no context provided for these numbers. Most viewers would want to know “50% of what?” They want the absolute risk reduction. Viewers should have been told that even though the women in the study were high risk, the incidence of breast cancer over 5 years was still very low. The story also does not mention that raloxifene does not reduce the incidence of ductal carcinoma in situ (DCIS, which tamoxifen does), so it is not clear that when the story says the benefits are equivalent between the two drugs, if it will hold true if they include all breast cancer events (including DCIS, which is found quite commonly these days).

The story also omits an important fact: the decrease in incidence of uterine cancer and clots in the raloxifene group was not statistically different from the tamoxifen group. Although uterine cancer and blood clots are mentioned as harms of treatment, there is no mention of how often they occur. Other harms such as cataracts and stroke are not mentioned.

No costs are mentioned. According to the website for the STAR trial, the cost of Raloxifene is about $75 per month, while Tamoxifen costs about $100 per month. Because these drugs have to be taken for long periods of time, cost is an important issue.

STAR ... Struck

  • 04.18.2006

I should also point out, in light of all the positive media surrounding the STAR study, the absurdity of Lilly having had to cop a plea and pay a $36,000,000 fine (“equitable disgourgement” indeed!) for allegedly disseminating information about the utility of Raloxifene “too soon.”

Too soon? For whom? Certainly not for patients, their spouses, children, extended families and friends. Certainly not for … doctors?

In the meantime, those who don’t find out about this important information today — or remember it for the year or so it’ll take for the supplemental application to be approved — won’t have the benefit of this very important (let alone newsworthy) information.

Something to ponder next time a pundit or politician pontificates on the need to further restrict the communication of health care information.

The big news today is that a federal judge ordered the Food and Drug Administration to rule on a human growth hormone product made by a Novartis AG unit, adding pressure for the agency to deal with the high-stakes question of generic copies of biotechnology drugs.

The decision by Ricardo M. Urbina, a judge in the U.S. District Court for the District of Columbia, came in response to a suit filed by Sandoz, a generics unit of Novartis, a Swiss pharmaceuticals maker. The suit, which named top officials of the FDA and its parent agency, the Department of Health and Human Services, alleged that the agency violated federal law by failing to either approve or reject Sandoz’s July 2003 application to market Omnitrope, a version of human growth hormone.

The judge’s opinion issued today — saying the agency is required to meet a statutory deadline in its decisions on whether to approve drugs — could strengthen the hands of drug companies. Judge Urbina wrote that the FDA had “identified no compelling reason for this court to excuse its delay.”

Silence, it seems, is not always golden.

Sandoz’s application “remains stuck in the ether,” the judge wrote, citing the “egregiousness of the delay.” The opinion says the FDA must meet statutory requirements, which include the option of giving the company a hearing before the Secretary of Health and Human Services about whether its drug is approvable.

The moral of the story is that delay based on silence doesn’t wash. Nor should it. Silence is the excuse of a weak argument. However, delay based on lack of expertise is a very good reason to defer a decision. Since Judge Urbina offered a hearing before the Secretary as a remedy, I predict that is precisely what will be offered.

Who wins? You make the call.

“Americans United” is a labor and Democrat party funded front group and they are wrong on the facts to boot. Why is there no caveat about where they get their funding at the end of their editorial in today’s USA Today? (See below.)

The design of the drug plan is exactly the same as that designed by President Clinton and supported by Families USA and the Democrats in 1999. How do they explain being for the drug plan before being against it? As for officials not wanting you to know about the enrollment breakdown, it’s right there on the damn HHS website, press release, etc. You would have to be an idiot not to see it … or Brad Woodhouse.

Actually there were 11 million seniors that lacked drug coverage before the program and 8.3 million have voluntarily signed up. My math puts me at 75 percent and we are not at May 15. 70 percent have reaped savings. that’s another way of saying 30 percent have not yet. As for the donut hole, guess what, a large chunk of seniors won’t hit it and those that will have actually purchased coverage that fills it.

The stand alone plans are not perfect. I would like to see drugs used to prevent disease and reduce spending overall in that fashion and you might need integrated health plans for that. But to suggest that the plan is corrupt is baseless beyond belief and comical considering Americans United were going to stoke the fires of resentment about the plan according to Democrat memo….Worse, to propose price controls as a panacea is simply being reduced to having no other message. Forcing biotech firms most of whom have piled up hundreds of milions of dollars of losses to sell half their medicines sold worldwide at the VA price (40 percent below wholesale) will be possible without destroying innovation or denying seniors access to breakthrough medicines is either delusional or writing for Americans United or a labor front group..oh wait that’s the same thing.

17 April 2006 USA Today - By Brad Woodhouse

The Medicare prescription drug program is costly, confusing and corrupt, and it has left millions of Americans to conclude that President Bush and Congress designed the plan with pharmaceutical and health insurance companies in mind, not seniors.

Medicare Part D is so hopelessly flawed that the enrollment deadline of May 15 must be extended to give Congress time to fix this debacle.

The deadline also must be extended to give people more time to sign up without penalty. It would be immoral to penalize seniors and the disabled for their failure to sign up for a plan that should have never been this difficult and confusing in the first place.

The Bush Administration claims that roughly 29 million Americans of the 42 million who are eligible have enrolled. What officials don’t want you to know is that almost three-quarters of those enrolled — some 21 million Americans — were dumped into Part D automatically. Only about half of those eligible for Part D who can voluntarily enroll have done so.

The reasons are clear: cost and confusion. A recent Washington Post/ABC News poll found that more than one in every three Americans who have enrolled reported that they have realized no savings — and when many begin to fall into the infamous “doughnut hole,” that figure is sure to rise.

In addition, millions of Americans have been deterred from enrolling because of the maze of confusion that has been a staple of the prescription drug plan. With more than 500 plans nationally, each with different premiums, co-pays and formularies — all of which are subject to change — it is little wonder that so many have yet signed up.

The fatal flaw in this law is that it prohibits Medicare from negotiating with pharmaceutical companies for lower prices, and from eliminating confusion by offering a simple and affordable plan to seniors directly from Medicare. The deadline must be extended so more people can sign up and so Congress can fix Part D to make it simple, affordable and guaranteed.

Brad Woodhouse is communications director for Americans United, an advocacy organization based in Washington

The amount of conservative complaining about Governor Romney’s health care plan has been nothing short of amazing to me. If you replace the words “health care” in the bill with “Medicare Part D” or “Medicare Advantage” you would have the same sort of vehicle for expanding coverage and promoting competition. Sure, there are things not to like about the Romney plan, including the employer fine and things it does not do, like provide enough low cost, non community rating choices. But how about fighting to fix those? As for the whining that it will be a model elsewhere, how about building our own models?

Finally, conservatives need some to educate themselves about what will really save health care dollars or at least make them more valuable. Health care financing models are only means to an end. The tidal wave of retirement needs to be reversed or transformed by enhancing health or prolonging productivity. Better health and longer life through more personalized medicine and preventive technologies are the key to revolutionizing health care. We need to start talking about and developing approaches that reward and capture these innovations. And we need both the guts and brains to carry the fight through or just get out of the way. It’s easy to gripe, hard to lead, harder to win.

Here at we have frequently commented that one of the basic differences between the various European health care models and our own is one between quality and equality. Europeans, by large margins, believe that equality of care is more important than quality of care while we in the US put quality first. We’ve also commented on the situation in the UK where a woman was denied Herceptin for treatment of her breast cancer because of NHS cost considerations. Well, an appeals court in London has ruled that the health service acted illegally when they denied her access to the drug. It seems that quality counts after all. This is a victory of sanity over philosophy.

The implications for the NHS system are profound, but equally important are the implications for those who would demand a purely evidence-based (read “cost-based”) system in the US. Are formularies limited to only the most cost-efficient treatments truly in the best interest of the public health? Clearly not.

Gil Morgan, chief executive of the NHS Confederation (which represents organizations within the British health care system sums it up NICEly, “These decisions are extremely difficult and best taken as close to the patient as possible.”

And that means in the doctor’s office — not Washington, DC.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog